Juvenile Arthritis News

The field of pediatric rheumatology is at a crossroads.

There is “wide variation” in the way clinicians measure and report the physician’s global assessment of disease activity in patients with juvenile idiopathic arthritis, according to data published in Rheumatology.

Systemic juvenile idiopathic arthritis and adult-onset Still’s disease have been combined into one entity called Still’s disease in new recommendations document presented at the EULAR 2023 Congress.

Coherus BioSciences’ adalimumab biosimilar, Yusimry, will make its debut in the U.S. marketplace this summer at an 85% discount compared with the originator Humira, according to the manufacturer.

Family income level is a significant predictor of longer hospital stays among children with lupus in the lowest income quartile, according to data published in Arthritis Care & Research.

The FDA has approved Celltrion USA’s Yuflyma as the ninth biosimilar to adalimumab for all eligible indications of the reference product, and the latest in a flood of biosimilars cleared for 2023 release in the United States.

The FDA has given the green light to a new autoinjector option for the interchangeable adalimumab biosimilar Cyltezo, just weeks ahead of its scheduled debut in the United States, according to a press release from the manufacturer.

Approximately 30% of patients with juvenile idiopathic arthritis develop temporomandibular joint involvement before transitioning to adult care, according to data published in Arthritis & Rheumatology.

Patients with juvenile idiopathic arthritis who demonstrate female sex, antinuclear antibody positivity and a positive family history have a higher risk for autoimmune thyroid disease, according to data published in Pediatric Rheumatology.

The FDA has approved a citrate-free, high-concentration formulation of the adalimumab biosimilar Hyrimoz, according to a press release from the manufacturer.